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\s=b\Tritiated imipramine binding in platelets
has been used to evaluate serotonin activity
in depression in previous studies. This arti-
cle examined this marker as a possible mea-
sure of central nervous system serotonergic
activity for depression in patients with Par-
kinson's disease (PD). The number of bind-
ing sites was significantly lower in de-
pressed patients with PD than in a healthy
control group. Patients with PD who were not
depressed had lower values than the com-
parison group, but this difference was not
significant. We also found a significant cor-
relation between the receptor site values in
platelets and cerebrospinal fluid levels of the
serotonin metabolite, 5-hydroxyindoleacetic
acid (r= .59), but this was independent of a
diagnosis of depression. Receptor site val-
ues were examined to identify appropriate
cutoff scores to predict depression in the
group of patients with PD. A maximum sensi-
tivity of 50% was achieved with a specificity
of 64%. Our results strongly support a gener-
alized alteration in serotonin metabolism in
depressed patients with PD, but tritiated
imipramine binding in platelets is not a use-
ful diagnostic tool for depression.(Arch Neurol. 1991 ;48:1052-1054)
T"1 he "serotonin hypothesis" of depres-
sion in Parkinson's disease (PD) is
based on the evidence of a generalized
deficiency of serotonin in patients with
PD and depression.1"' The cerebrospinal
fluid (CSF) concentration ofthe seroto¬
nin metabolite, 5-hydroxyindoleacetic
acid (5-HIAA), is reduced in patients
with PD compared with age-matched
controls1; levels are even lower in pa¬
tients with depression.3 Serotonin also
plays a role in depression among indi¬
viduals who do not have PD, since CSF
5-HIAA levels are lower in depressed
patients and in suicide victims.6,7
An alternative measure of serotoner¬
gic function is tritiated imipramine (3H-
imipramine) binding, which measures
presynaptic serotonergic receptor sites
and has been examined in platelets and
brain.8 Tritiated imipramine binding is
lower in the platelets of patients with¬
out PD but with depression and is re¬
duced in the brains of depressed pa¬
tients dying of natural causes or suicide
when compared with the brains from
those who did not commit suicide.9 How¬
ever, others have found no difference in
brain or platelet binding between de¬
pressed and nondepressed individ¬
uals.10,11
Correlations between platelet and
brain 3H-imipramine binding capacity in
animal studies12 suggest that platelet
binding may reflect central nervous sys¬
tem activity. Although Raisman et al13
found 3H-imipramine binding decreased
in the brains of patients with PD (in
whom depression was not assessed),
earlier reports indicated no difference
between individuals with PD and con¬
trols.14 Schneider et al16 found platelet
binding reduced in depressed patients
with PD. These conflicting studies used
small groups and the diagnostic infor¬
mation concerning depression was not
systematically obtained.
This study sought to examine the re¬
lationship among depression, CSF 5-
HIAA, and 3H-imipramine binding in
platelets in patients with PD. Second, it
sought to determine whether 3H-imip-
ramine binding in platelets could be a
sensitive and specific marker for de¬
pression in these patients.
SUBJECTS AND METHODS
Patient Group
Seventy patients with idiopathic PD(mean age, 66.9 ±9.1 years) participated in
this study. The diagnosis of idiopathic PD
was defined by the presence of at least two of
the following four features: tremor, gait dis¬
order, bradykinesia, and rigidity. Clinical
history and other physical symptoms had to
be consistent with the idiopathic form ofthe
disease. Patients were excluded if there was
evidence implicating another cause for the
parkinsonism (eg, phenothiazine exposure or
history of encephalitis) and if they had taken
any type ofantidepressant medication or oth¬
er psychoactive drug in the last 60 days.
However, patients who were taking dopa¬
mine agonists or dopamine precursors or an-
ticholinergics for PD were included. The
type and dose of medication were recorded.
Control Group
This group consisted of 53 age-matched,
healthy elderly individuals (mean age,
66.5 ± 4.7 years) who were accompanying pa¬
tients to the medical center. This included
spouses, companions, and significant others
who were not blood relatives of the patient
group. These individuals were screened to
eliminate central nervous system disease, a
history of major depression or other psychi¬
atric illness, or other life-threatening medi¬
cal illnesses. Individuals were excluded if
they had taken antidepressant medication
within the past 60 days.
Procedures
After giving informed consent all subjects
received the following assessments.
Standardized Medical History.—This in¬
cluded a record of all major medical and neu¬
rologic problems, psychiatric treatment his¬
tory, and current medications. For the
patients with PD, a detailed history of the
onset of the disease was taken and all treat¬
ment regimens were recorded.
PD Severity Ratings.—The Unified Par¬
kinson's Disease Rating Scale16 was used to
assess the presence and severity of motor
manifestations. Those items that assess
mentation, behavior, and mood (items 1
through 4) were excluded because they were
measured with alternate instruments de¬
scribed below. The maximum score possible
on the remaining items is 172, with higher
scores indicating more severe motor distur¬
bance. The Schwab and England17 inventory
of Activities of Daily Living7 was used. This
inventory rates by percentage the degree of
independence in Activities of Daily Living,
with 100% referring to total independence
and 0% indicating the patient is bedridden
with impairment of vegetative functions.
The Hoehn and Yahr Scale18 was also com¬
pleted. This six-stage index ranges from 0("no sign of disease") to 5 ("bedridden or
wheelchair bound").
Mental Status.—The modified Mini-Men¬
tal State Examination was administered to
assess intellectual function. This modifica-
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Table 1.—Comparison of Depressed and Nondepressed Patients With Parkinson's
Disease (PD) and Healthy Elderly Volunteers*
Group HDRS Kd
Patients with PD
Depressed 17.4 ± 4.5t 1.2 740.9 ± 198 
Nondepressed 56 4.2 ± 3.4 862.0 ± 352
Controls 53 4.0 ± 4.2t 2.1 0.8 950.3 ± 255 
*HDRS indicates Hamilton Depression Rating Scale score; Kd, affinity constant; and B™,,, number of recep¬
tor sites. The total group (patients with PD) was classified as described: depressed, Hamilton Score 12 or more;
nondepressed, Hamilton Score less than 12.
tGroups were significantly different (P < .01).
^Groups were significantly different (P < .05).
tion ofthe procedure described by Folstein et
al19 includes additional items that measure
naming, language, and attention and has a
maximum score of 57. The mean modified
Mini-Mental State score for healthy elderly
individuals is 52.5 ( ± 4.3).a
Psychiatric Evaluation.—A standard¬
ized semistructured interview for the Hamil¬
ton Depression Rating Scale (HDRS)21 was
administered. Based on previous findings,1,2
those patients with HDRS scores greater
than 12 were classified as clinically
depressed.3H-Imipramine Binding.—Binding of  -
imipramine in platelets was determined us¬
ing the method described by Briley et al22 and
modified by Asarch et al.23
CSF Studies.-Nineteen of the 70 pa¬
tients with PD participated in an extended
study of biogenic amine metabolites in CSF.
These patients were selected because they
had cognitive or affective complaints and
were admitted to the General Clinical Re¬
search Center to complete all assessments.
In addition to the HDRS, psychiatric diag¬
noses for depression were made according to
the criteria ofthe Diagnostic and Statistical
Manual, Revised Third Edition," using the
Structured Clinical Interview2" completed by
a trained interviewer with the patient (and
an informant when available).
Lumbar puncture for CSF studies was
performed after 18 hours ofbed rest. Twenty
milliliters of CSF was obtained for biochemi¬
cal analysis. High-pressure liquid chroma¬
tography with amperometric detection was
used to measure 5-HIAA and homovanillic
acid by a method previously described.
Data Analysis
For 3H-imipramine-bincling studies, Scat-
chard analysis was used to determine the
number of receptor sites (BmaK) and the affini¬
ty constant (Kd)3' for each subject. Tritiated
imipramine-binding results were correlated
with demographic and disease severity vari¬
ables. Group mean comparisons were used to
examine differences in binding measures be¬
tween controls and patients. Pearson corre¬
lations were used to examine the association
between CSF 5-HIAA measures and platelet
binding measures. Nonparametric tech¬
niques were used to examine the sensitivity
and specificity2' of platelet binding for as¬
sessment of depression in PD.
RESULTS
Tritiated imipramine-binding mea¬
sures for the PD group and the control
group were initially compared using a t
test. This comparison yielded a signifi¬
cant difference between the two groups(P=s.05). Patients with PD were then
classified as depressed, using an HDRS
score of 12 or greater for depression, or
not depressed. The 3H-imipramine-
binding measures for the two PD groups
and the control group are given in Table
1. An analysis of variance of the Bmax
values yielded a significant F test(P<.05) for the comparison of de¬
pressed patients with PD, nonde¬
pressed patients with PD, and the con¬
trol group. Post hoc analysis
demonstrated significantly lower Bmax
values in the depressed patients with
PD than in the controls. The group
mean value for the nondepressed pa¬
tients with PD fell between the other
two groups, but was not significantly
different from either. Based on effect
size reported by Schneider et al,10 this
study had sufficient group size to
achieve 65% power for detecting such a




The mean duration of illness in the PD
group was 8.6 (±2.2) years and the
mean Unified Parkinson's Disease Rat¬
ing Scale score was 41.8 (±26.1). The
mean Hoehn and Yahr rating in the PD
group was 2.7 (±.79), with 39.1% re¬
ceiving a score of 1 or 2 (mild disease),
48.4% receiving a score of 3 (moderate
severity), and 12.5% receiving a score of
4 or 5 (marked severity). The mean
Schwab and England rating was 68.3%(±24.1%) with 23.8% of the patients
experiencing serious disability, scoring
below 50%. None of these measures
were significantly correlated with Bmax
or Kd values.
The mean modified Mini-Mental
State score in the PD group was 44.7(±11.5). This is significantly lower(P<.05) than the mean for the control
group (52.3 ±3.4). However, no signifi¬
cant correlation was noted between this
measure and Bniaj. or Kd values.
Fifty-five (78.6%) patients were tak-
Table 2.—Comparison of
Cerebrospinal Fluid (CSF) Metabolites
and Binding Measures in Depressed





(n = 8)_(n - 11)
HDRS 16.1 (7.1)t 5.8(3.6)t
CSF 5-HIAA 14.2(6.4) 18.8(6.8)
CSF HVA 52.7(34.3) 30.5(12.1)
Kd 1.2(0.72) 1.5(0.72)
B„„ 826.9 (253) 904.2 (384)
*HDRS Indicates Hamilton Depression Rating
Scale; 5-HIAA, 5-hydroxyindoleacetlc acid; HVA, ho¬
movanillic acid; Kd, affinity constant; and Bma„ num¬
ber of receptor sites. Numbers in parentheses are
SDs.
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Relationship between the amount of 5-hydrox-
ylndoleacetic acid (5-HIAA) in cerebrospinal
fluid (CSF) and the number of tritiated imipra¬
mine binding sites in platelets of patients with
Parkinson's disease. Bmax indicates number of
receptor sites.
ing parkinsonian medication. The corre¬
lation between the dose of medication
and the Bmax was not significant(r=-.2).
3H-lmipramine-Binding
and CSF Measures
Eight (42%) of the 19 patients who
had lumbar punctures for the CSF stud¬
ies were diagnosed as having major de¬
pression ordysthymia. Theyhad a mean
HDRS score of 16.1 ± 7.1, which repre¬
sents depression of mild to moderate
severity, compared with a mean HDRS
score of 5.8 ±3.6 in the nondepressed
patients (P<.05). The CSF 5-HIAA and
the 3H-imipramine binding values for
these patients are given in Table 2. A
significant correlation was noted be¬
tween Bm„ values and CSF 5-HIAA(r=.59; P<.01) (Figure) but not CSF
homovanillic acid (r=.39; P>.1). The
Kd values did not correlate with either
CSF metabolite measure.
The mean CSF 5-HIAA level in the
depressed group was lower than in the
nondepressed group (14.2 ±6.4 vs
18.8±6.8 ng/mL). This difference was
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not statistically significant, perhaps due
to our small sample size. Based on our
previous work,1 it was estimated that
this study yielded low power for this
comparison (0.25).
Sensitivity and Specificity of 3H-lmipramine
Binding for Depression in PD
The sensitivity and specificity of  -
imipramine binding to detect depres¬
sion in PD was examined. A Bmax cutoff
value of800 correctly classified the max¬
imum number of patients; 37 (53%) of
the 70 patients with PD were correctly
identified as depressed or not de¬
pressed. This value yielded a specificity
of 64% and a sensitivity of 50% for de¬
pression among the PD group.
COMMENT
This study further supports an alter¬
ation in serotonin in PD. First, :!H-imip-
ramine binding in platelets is reduced in
patients with PD. A closer examination
of these patients demonstrates that pa¬
tients with depression and PD have sig¬
nificantly fewer binding sites than con¬
trols. Patients with PD who were not
depressed had BBmaN values that fell be¬
tween the controls and the depressed
group, although they were not signifi¬
cantly different. Second, platelet bind¬
ing values significantly correlate with
CSF 5-HIAA levels, suggesting that
this peripheral measure may reflect
central serotonergic activity. Together,
these results provide additional evi¬
dence for a generalized serotonergic ab¬
normality that may be associated with
depression in PD.
The binding values in this study were
similar to those reported by Suranyi-
Cadotte et al,14 who found no difference
between patients with PD and a com¬
parison group. However, the sample
size was much smaller in their study.
Schneider and coworkers10 found a 22%
decrease in 3H-imipramine platelet
binding in subjects with PD compared
with controls. Four of the nine patients
with PD had either major depression or
dysthymic disorder that may have con¬
tributed to the reported difference, al¬
though this was not systematically ex¬
amined. This study demonstrated a
10.9% difference in Bmax values with a
large group size.
This work represents the first report
of a correlation between CSF and plate¬
let measures of serotonergic activity. It
is usually assumed that CSF markers
reflect only nonspecific changes in brain
chemistry, but in suicide victims there
is a correlation between CSF 5-HIAA
and 3H-imipramine-binding sites in the
frontal cortex.28 In depressed patients
with PD, Mayberg et al29 found lowered
metabolism in the caudate and in the
inferior orbital-frontal cortex, where a
serotonergic mechanism for this frontal
hypometabolism has been postulated
previously.30 Significant loss of large
neurons in the ascending serotonergic
pathway ofthe dorsal raphe nucleus and
decreased serotonin concentrations in
the projection areas in the frontal cortex
have also been reported in patients with
PD.31
Although pervasive, the serotonergic
deficit may not parallel deterioration of
the dopamine system. Our previous
work indicates no correlation between
CSF 5-HIAA and variables associated
with disease severity such as age, motor
manifestation, or the use of dopamine
precursors or agonists.3 Similarly, this
study found no association between
these variables and 3H-imipramine-
binding measures.
A peripheral marker for depression in
PD would be useful because symptoms
of depression and PD may overlap.
When a Bniils value was chosen to provide
maximum correct classification of de¬
pression among patients with PD, the
specificity and sensitivity of the mea¬
sure were too low to be useful as a
screen. Despite this, the decrease in
Bmax in depressed patients with PD and
the correlation between CSF and plate¬
let measures support a major alteration
in serotonergic metabolism in PD that
may explain some of the behavioral
manifestations of PD.
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